Clinical Trials Directory

Trials / Unknown

UnknownNCT06224296

The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
Shanghai Cell Therapy Group Co.,Ltd · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood. It's also postulated that DFPP could boost immune cells through removing certain inflammatory cytokines and blood lipids.

Detailed description

In this study, 3 groups of subjects will be recruited based on the indications of using DFPP. Estimated 100 sub-healthy subjects will be enrolled in the Group A (inflammatory cytokine group), the inflammatory cytokine panel will be tested at baseline, immediately and 1, 3, 6 months after using DFPP. Similarly estimated 100 subjects with elevated blood lipid or cholesterol will be enrolled in Group B (lipids group), the lipid panel will be tested at the same timeline as Group A. Estimated 50 subjects who are likely to have toxic metal ions accumulated (eg. using make-up for long term, working exposure) will be enrolled in Group C (toxic metal ions group), the specific metal ions will be tested before and after using DFPP. Tests related to immune cells will also be conducted in Group A and B at baseline, immediately and 1, 3, 6 months after using DFPP.

Conditions

Interventions

TypeNameDescription
DEVICEDFPPOne session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
DEVICEDFPPOne session of blood purification using DFPP to remove lipids in peripheral blood.
DEVICEDFPPOne session of blood purification using DFPP to remove toxic metal ions.

Timeline

Start date
2024-03-01
Primary completion
2024-12-31
Completion
2025-03-01
First posted
2024-01-25
Last updated
2024-01-25

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06224296. Inclusion in this directory is not an endorsement.